Synonym
GT-1061; GT1061; GT 1061; GT-1061 HCl; GT-1061 hydrochloride
IUPAC/Chemical Name
2-(4-Methylthiazol-5-yl)ethyl nitrate hydrochloride
InChi Key
AFJHNVYIRRYUJM-UHFFFAOYSA-N
InChi Code
InChI=1S/C6H8N2O3S.ClH/c1-5-6(12-4-7-5)2-3-11-8(9)10;/h4H,2-3H2,1H3;1H
SMILES Code
O=[N+]([O-])OCCC1=C(C)N=CS1.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
224.66
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Beninger RJ, Forsyth JK, Van Adel M, Reynolds JN, Boegman RJ, Jhamandas K. Subchronic MK-801 behavioural deficits in rats: partial reversal by the novel nitrate GT 1061. Pharmacol Biochem Behav. 2009 Feb;91(4):495-502. doi: 10.1016/j.pbb.2008.09.003. Epub 2008 Sep 10. PMID: 18834899.
2: Thatcher GR, Bennett BM, Reynolds JN. NO chimeras as therapeutic agents in Alzheimer's disease. Curr Alzheimer Res. 2006 Jul;3(3):237-45. doi: 10.2174/156720506777632925. PMID: 16842101.
3: Thatcher GR, Bennett BM, Dringenberg HC, Reynolds JN. Novel nitrates as NO mimetics directed at Alzheimer's disease. J Alzheimers Dis. 2004 Dec;6(6 Suppl):S75-84. doi: 10.3233/jad-2004-6s614. PMID: 15665418.
4: Thatcher GR, Bennett BM, Reynolds JN. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr Alzheimer Res. 2005 Apr;2(2):171-82. doi: 10.2174/1567205053585945. PMID: 15974915.
5: Abdul-Hay S, Schiefer IT, Chandrasena RE, Li M, Abdelhamid R, Wang YT, Tavassoli E, Michalsen B, Asghodom RT, Luo J, Thatcher GR. NO-SSRIs: Nitric Oxide Chimera Drugs Incorporating a Selective Serotonin Reuptake Inhibitor. ACS Med Chem Lett. 2011 Sep 8;2(9):656-661. doi: 10.1021/ml2000033. PMID: 21927645; PMCID: PMC3171965.
6: Bennett BM, Reynolds JN, Prusky GT, Douglas RM, Sutherland RJ, Thatcher GR. Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester. Neuropsychopharmacology. 2007 Mar;32(3):505-13. doi: 10.1038/sj.npp.1301054. Epub 2006 Mar 8. PMID: 16525416.
